| Abbott Buys AP214 Hormone From Action Pharma For $110 Million - Wall Street Journal |
|
|
Wall Street Journal Abbott Laboratories (ABT) took another step to enhance its renal-care pipeline by agreeing to acquire AP214, a hormone analogue that may prevent acute kidney injury during cardiac surgery, from Action Pharma A/S for $110 million in cash. Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b |